About US
Contact us
-
ASCO: Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approvalCHICAGO—Pfizer and Astellas’ Xtandi is gunning for a new indication in prostate cancer, and they say Sunday's new data complement the supporting evidence they’ve already generated. Sunday at the Amer2019/5/30
-
ASCO: Gilead touts CAR-T franchise with Yescarta analyses, early data on pipeline drugAs other parts of its business slump, Gilead Sciences has zeroed in on cell therapy, hoping to lead a wave into that new market. And at the American Society of Clinical Oncology's (ASCO's) annual m2019/5/30
-
All the ASCO skinny: Lynparza's pancreatic win, Amgen's KRAS spotlight, Merck's history-busting and moreThe cancer world flocked to Chicago over the weekend for what's traditionally been the biggest oncology meet-up of the year. But this year's American Society of Clinical Oncology line-up didn't exact2019/5/29
-
ASCO: AZ, Merck's Lynparza fends off pancreatic cancer, cutting progression risk in halfCHICAGO—AstraZeneca and Merck’s Lynparza is on a roll when it comes to making headlines at the American Society of Clinical Oncology (ASCO) annual meeting—and doing it in some of the toughest-to-trea2019/5/29
-
Four pharma firms accused of anti-competitive practices in UKThe UK Competition and Markets Authority (CMA) has accused Alliance Pharmaceuticals, Focus, Lexon and Medreich of avoiding competition for anti-nausea drug, prochlorperazine. Indicated for the treatm2019/5/28
-
Lilly starts selling half-price version of Humalog insulinEli Lilly has announced the market launch of a half-price, generic version of its Humalog insulin. Called Insulin Lispro Injection, the product is available in a vial or within a KwikPen. Insulin Lis2019/5/28
-
Chugai Pharmaceutical to build new $1bn research lab in JapanChugai Pharmaceutical has revealed plans to establish a core research laboratory at its business site in Yokohama, Kanagawa Prefecture, Japan. Named Chugai Life Science Park Yokohama, the new facilit2019/5/27
-
Janssen’s Invokana secures FDA priority review statusJanssen Pharmaceutical has received priority review from the US Food and Drug Administration (FDA) for its Invokana (canagliflozin) medicine in type 2 diabetes (T2D) patients with chronic kidney dise2019/5/27
-
Novartis CEO says Zolgensma won't cost anywhere near the $4M to $5M once quotedNovartis has said its forthcoming spinal muscular atrophy gene therapy could be cost-effective at a price of up to $5 million, but now the company's CEO says to think "far lower." As the Swiss drug2019/5/24
-
Array's ‘extremely compelling’ new colon cancer data spark blockbuster talkThe news that Array BioPharma’s clinical trial of its triplet therapy for colon cancer extended lives in a trial of patients with the BRAF mutation sent the company’s shares up 23% on Tuesday—a run t2019/5/24